Skip to main content

Table 4 Univariate and multivariate analyses for overall survival (OS)

From: Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients

Variable Univariate Multivariate
HR (95%CI) P value HR (95%CI) P value
Age, years   0.202   
  ≤ 50 1.0    
 >50 0.78 (0.53–1.14)    
Gender   0.411   
 Female 1.0    
 Male 1.30 (0.70–2.43)    
Vascular invasion   0.007   0.001
 No 1.0   1.0  
 Yes 1.73 (1.17–2.57)   2.09 (1.38–3.18)  
Extrahepatic metastasis   0.006   0.038
 No 1.0   1.0  
 Yes 1.72 (1.17–2.54)   1.53 (1.02–2.30)  
ALBI grade   < 0.001   <0.001
 I 1.0   1.0  
 II 2.35 (1.59–3.45)   2.28 (1.54–2.37)  
AFP reduction> 50%   < 0.001   0.003
 No 1.0   1.0  
 Yes 0.44 (0.30–0.66)   0.50 (0.32–0.80)  
PIVKA-II reduction> 50%   < 0.001   0.006
 No 1.0   1.0  
 Yes 0.49 (0.33–0.72)   0.54 (0.35–0.84)  
Baseline AFP level > 400 ng/ml   0.001   0.001
 No 1.0   1.0  
 Yes 2.27 (1.43–3.62)   2.31 (1.44–3.70)  
Baseline PIVKA-II level > 400 mAU/ml   0.142   
 No 1.0    
 Yes 1.51 (0.87–2.61)